Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Global antibiotic consumption rates increased by 46 percent in the last two decades, according to the first study to provide longitudinal estimates for human antibiotic consumption covering 204 countries from 2000 to 2018, published in Lancet Planetary Health by the Global Research on Antimicrobial Resistance (GRAM) Project.

Map showing the global antibiotic consumption per country, showing DDDs (defined daily doses) per 1000 per day.
Global antibiotic consumption, showing DDDs (defined daily doses) per 1000 per day

The excess and inappropriate use of antibiotics is an important driver of drug resistant infections, yet data on antibiotic consumption are scarce. Global Research on Antimicrobial resistance (GRAM), which includes researchers from the University of Oxford, the Mahidol Oxford Tropical Medicine Research Unit (MORU), and the Institute for Health Metric and Evaluation (IHME), used a novel approach that deployed statistical modelling techniques, and incorporated multiple data sources and types, such as large-scale household surveys in low-and middle-income countries, pharmaceutical sales data, and antibiotic consumption data from the World Health Organisation (WHO) and the European Centre for Disease Prevention and Control (ECDC).

The study provides a comparative analysis of total antibiotic consumption rates in humans globally, expressed in the WHO metric of defined daily doses (DDD) per 1000 population per day. This equates to the proportion of people receiving antibiotics on a single day (on each single day in that year) in a given country.

“Understanding the patterns of global antibiotic consumption can help us address a number of public health challenges, from combating drug resistant infections to providing access to basic treatment”, Dr Annie Browne, data scientist, GRAM geospatial modeller, and the study’s first author.

The key findings:

  • High rates of antibiotic consumption were seen in North America, Europe and the Middle East, which were contrasted by very low rates of consumption in sub-Saharan Africa and parts of Southeast Asia.
  • Total antibiotic consumption rates showed a nearly ten-fold variation between countries, ranging from as low as 5·0 DDD to 45·9 DDD per 1000 population per day.
  • Between 2000 and 2018, global antibiotic consumption rates increased by 46% (from 9·8 to 14.3 DDD per 1000 population per day).
  • In high-income countries, consumption rates remained stable between 2000 and 2018
  • In low- and middle-income countries, there was a 76% increase observed between 2000 and 2018 (from 7·4 to 13·1 DDD per 1000 per day).
  • The largest increases in antibiotic consumption rates were seen in the North Africa and Middle East region (111% increase) and South Asia (116%).
  • Large variations in the proportion of antibiotics classes used in different geographic contexts.
  • The highest rates of broad-spectrum penicillin consumption were observed in the High-Income super-region and the lowest in South Asia.
  • In South Asia, consumption rates for fluoroquinolones increased 1.8 fold and for third-generation cephalosporin 37 fold during the study period.

“These findings reveal the huge task ahead, implementing and delivering the WHO Global Action Plan on Antimicrobial Resistance, which relies on optimising antibiotic use and reducing the incidence of infections”, said Professor Christiane Dolecek, the study’s lead author and GRAM scientific lead based in Oxford University’s Centre for Tropical Medicine and Global Health and the Mahidol Oxford Tropical Medicine Research Unit (MORU). “It is imperative to curb the unnecessary demand for antibiotics and combat antimicrobial resistance by improving drinking water and sanitation, vaccine coverage and the availability of rapid diagnostic testing, whilst also increasing access and stewardship of antibiotics when and where they are needed. We hope that this seminal platform and first global country-level benchmarking of antibiotic consumption and usage over a 19-year period up to the pre-COVID-19 era can help inform future interventions to optimise antibiotic use and consumption.”

WHO World Antibiotic Awareness Week (WAAW)

The publication of the study coincides with the WHO World Antibiotic Awareness week, 18-24 November 2021. The 2021 theme, Spread Awareness, Stop Resistancecalls on One Health stakeholders, policymakers, health care providers, and the general public to be Antimicrobial Resistance (AMR) Awareness champions. A link to more information is available here:

This study was funded by the UK Department of Health and Social Care’s Fleming Fund, the Wellcome Trust, and the Bill and Melinda Gates Foundation.

Read the full publication ‘Global antibiotic consumption and usage in humans, 2000-2018: a spatial modelling study’ on the Lancet Planetary Health website

This story is also posted on the University of Oxford website

Similar stories

Field evaluation of EasyScan GO: a digital malaria microscopy device

Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.

Registration is open for The Global Health Network Conference 2022

To tackle disease we need evidence to be generated through every type of health research study. This conference aims to bring together health research teams, organisations, health-workers, policy makers and practitioners to explore together how health research can be embedded into every healthcare setting. Join us at The Global Health Network Conference 2022 at the University of Cape Town, South Africa, 24 – 25 November 2022

The inside story of Recovery: how the world’s largest COVID-19 trial transformed treatment – and what it could do for other diseases

Two years ago, the Recovery trial transformed the care of COVID patients with its dexamethasone announcement. Within four hours, the steroid was included in NHS treatment recommendations. Almost overnight, treatment of COVID patients around the world changed completely. It has been estimated that dexamethasone may have saved a million lives in the first nine months following the announcement. Recovery is a groundbreaking scientific machine which, from the outset, moved at unprecedented speed. In the first 100 days alone, the trial produced three groundbreaking results that would completely reshape COVID care.

Gail Carson chair of GOARN

Dr Gail Carson from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) is nominated chair of WHO Global Outbreak Alert & Response Network (GOARN)

Enhanced vaccination against Japanese encephalitis virus could reduce encephalitis prevalence by one third in SE Asia

Encephalitis is a worldwide public health issue, with a substantially high burden among children in Southeast Asia. A large study of the causes of childhood encephalitis in SE Asia suggests that enhanced and effective vaccination against the Japanese encephalitis virus alone could reduce encephalitis prevalence by one third.

RECOVERY trial celebrates two-year anniversary of life-saving dexamethasone result

Two years ago, the RECOVERY trial gave the world its first breakthrough against coronavirus: the discovery that an inexpensive steroid pill, dexamethasone, reduced deaths by up to a third from COVID-1. Within hours, the result was breaking news across the world and hospitals were adopting the drug into the standard care given to all patients with COVID-19. In the nine months following the discovery, dexamethasone saved an estimated one million lives worldwide.